| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma A Rosenwald, G Wright, WC Chan, JM Connors, E Campo, RI Fisher, ... New England Journal of Medicine 346 (25), 1937-1947, 2002 | 4754 | 2002 |
| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3198 | 2019 |
| A prognostic score for advanced Hodgkin's disease D Hasenclever, V Diehl, JO Armitage, D Assouline, M Björkholm, ... New England Journal of Medicine 339 (21), 1506-1514, 1998 | 2196 | 1998 |
| Stromal gene signatures in large-B-cell lymphomas G Lenz, G Wright, SS Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, ... New England Journal of Medicine 359 (22), 2313-2323, 2008 | 1964 | 2008 |
| Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells SS Dave, G Wright, B Tan, A Rosenwald, RD Gascoyne, WC Chan, ... New England Journal of Medicine 351 (21), 2159-2169, 2004 | 1633 | 2004 |
| Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma A Rosenwald, G Wright, K Leroy, X Yu, P Gaulard, RD Gascoyne, ... The Journal of experimental medicine 198 (6), 851-862, 2003 | 1340 | 2003 |
| The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, ... Cancer cell 3 (2), 185-197, 2003 | 1075 | 2003 |
| Molecular diagnosis of Burkitt's lymphoma SS Dave, K Fu, GW Wright, LT Lam, P Kluin, EJ Boerma, TC Greiner, ... New England Journal of Medicine 354 (23), 2431-2442, 2006 | 1052 | 2006 |
| Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a … MHJ Van Oers, R Klasa, RE Marcus, M Wolf, E Kimby, RD Gascoyne, ... Blood 108 (10), 3295-3301, 2006 | 767 | 2006 |
| Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01 F d'Amore, T Relander, GF Lauritzsen, E Jantunen, H Hagberg, ... Journal of Clinical Oncology 30 (25), 3093-3099, 2012 | 647 | 2012 |
| Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction S Bea, A Zettl, G Wright, I Salaverria, P Jehn, V Moreno, C Burek, G Ott, ... Blood 106 (9), 3183-3190, 2005 | 533 | 2005 |
| Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project DD Weisenburger, KJ Savage, NL Harris, RD Gascoyne, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (12), 3402-3408, 2011 | 492 | 2011 |
| Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study MHJ Van Oers, M Van Glabbeke, L Giurgea, R Klasa, RE Marcus, M Wolf, ... Journal of clinical oncology 28 (17), 2853, 2010 | 372 | 2010 |
| Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model A Hollender, S Kvaloy, O Nome, E Skovlund, K Lote, H Holte Annals of Oncology 13 (7), 1099-1107, 2002 | 351 | 2002 |
| Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project J Delabie, H Holte, JM Vose, F Ullrich, ES Jaffe, KJ Savage, JM Connors, ... Blood, The Journal of the American Society of Hematology 118 (1), 148-155, 2011 | 346 | 2011 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 325 | 2022 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 304 | 2021 |
| Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial J Bergh, T Wiklund, B Erikstein, E Lidbrink, H Lindman, P Malmström, ... The Lancet 356 (9239), 1384-1391, 2000 | 304 | 2000 |
| Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival A Wiestner, M Tehrani, M Chiorazzi, G Wright, F Gibellini, K Nakayama, ... Blood, The Journal of the American Society of Hematology 109 (11), 4599-4606, 2007 | 300 | 2007 |
| CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial E Osby, H Hagberg, S Kvaløy, L Teerenhovi, H Anderson, ... Blood, The Journal of the American Society of Hematology 101 (10), 3840-3848, 2003 | 250 | 2003 |
